SciClone hepatitis drug falls short in phase III trial (Chronic Hepatitis C)

SciClone hepatitis drug falls short in phase III trial
Pharmaceutical Business Review - SciClone Pharmaceuticals' investigational treatment for hepatitis C, Zadaxin, has failed to meet its primary efficacy endpoints in a phase III trial.

Bachem Double Disappointment Underscores Risk
New Ratings - SCLN) Zadaxin failing in Phase III for Hepatitis C removes significant upside potential share Bachem (BANB.EB

GlobeImmune, Inc. Relocates Corporate Headquarters
BioSpace - 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005

Hepatitis C Is An Increasing Burden, Finds Report
Staff Nurse - Most patients could be successfully treated, she said. ' The success of treatment relies on people coming forward for testing. ' Hepatitis C Is An Increasing Burden, Finds Report Chronic hepatitis C infection has led to severe

SciClone to Host Conference Call December 14, 2005 to Discuss ZADAXIN Phase 3 Hepatitis C Results and Interim
Pharma Live - that it will report ZADAXIN(r) phase 3 hepatitis C results and interim phase 2 malignant melanoma data evaluated in two phase 3 hepatitis C clinical trials in the United